Evaluating KRAS mutant allele dosage impact on first-line PDAC outcomes

Higher mutant KRAS dosage linked to worse survival in PDAC patients treated with 1L therapy

INDICATION

Pancreatic

BIOMARKER

KRAS

Related cases

Abstract pixelated pattern in warm orange tones with diagonal lines and irregular shapes.

Analyzing specific KRAS variants and treatment outcomes in colorectal cancer

Light green statistical box plot graph on a white background, low contrast.

Characterizing KRAS variants in NSCLC with multimodal RWD

Unable to determine image content.

Validating FFPE-based genomic profiling in pancreatic cancer